Fetal Bovine Serum Market Updates

Fetal Bovine Serum Market size was valued at USD 1.79 Billion in 2023 and is poised to grow from USD 2.04 Billion in 2024 to USD 5.88 Billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).

Fetal bovine serum providers should focus on solving the ethical concerns surrounding the production of their product to maximize business scope. Targeting countries where investments in cell research are high is expected to offer better returns on investments for fetal bovine serum providers. Fetal bovine serum companies should also try to achieve consistency in different batches of fetal bovine serum to improve consistency of results.   'Thermo Fisher Scientific Inc. (US)', 'Merck KGaA (Germany)', 'GE Healthcare (US)', 'Tissue Culture Biologicals (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Atlanta Biologicals Inc. (US)', 'Sigma-Aldrich Corporation (US)', 'Rocky Mountain Biologicals (US)', 'PAN-Biotech GmbH (Germany)', 'Bovogen Biologicals Pty Ltd. (Australia)', 'Biowest SAS (France)', 'Biological Industries Israel Beit Haemek Ltd. (Israel)', 'Corning Incorporated (US)', 'Sera Laboratories International Ltd. (UK)', 'Caisson Laboratories Inc. (US)', 'Hyclone Laboratories Inc. (US)', 'Lanzhou Minhai Biotechnology Co., Ltd. (China)', 'Moregate BioTech (UK)', 'Gemini Bio-Products (US)', 'Lampire Biological Laboratories (US)'

Surging use of monoclonal antibodies, vaccines, and cell therapies for the treatment of various diseases has resulted in high demand for biopharmaceutical research around the world. Fetal bovine serum is a key supplement in cell culture media required for biopharmaceutical production thereby making this a key fetal bovine serum market growth driver.  

Use in 3D Cell Culture: Investments in 3D cell culture are increasing rapidly around the world and this is expected to present new opportunities for fetal bovine serum providers in the future. Fetal bovine serum can play a vital role in maintaining stability of complex 3D cell culture systems over the coming years and boost revenue generation potential for market players.   

North America is forecasted to account for a high fetal bovine serum market share on a global level. Rising healthcare research and development activity, growing emphasis on improving biopharmaceutical production, and presence of multiple pharmaceutical companies are key factors allowing this region to maintain its dominant stance. The United States is slated to spearhead revenue generation in North America followed by Canada over the coming years. Availability of supportive government funding for medical research and rising investments in stem cell and regenerative medicine research are also slated to create new opportunities for fetal bovine serum providers in this region.